ECG Derived Respiration for Automated Screening of Sleep Disordered Breathing in Chronic Heart Failure Patients

The prevalence of sleep disordered breathing (SDB) reaches more than 50% in chronic heart failure patients (CHF). The main consequence is an increase risk of fatal and non-fatal cardiovascular events. A treatment by continuous positive airway pressure (CPAP) or adaptative servo-ventilation (ASV) reduces this risk. Nevertheless, 75% of severe SDB cases remains undiagnosed and untreated especially due to cost and time delay for polysomnography examination which is the gold standard for SDB diagnosis. Indeed, alternative methods are developed. Some methods, based on nocturnal ECG analysis showed promising results but they are not validated and adapted for cardiac population. Thus, the goal of present study is to test the accuracy of ECG derived respiration signal to screen SDB in a CHF population.

Study Overview

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Grenoble, France, 38000
        • Chu de Grenoble
      • Saint-etienne, France, 42000
        • CHU de Saint-Etienne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Heart failure patients with sleep apnea syndrom

Description

Inclusion Criteria:

  • chronic heart failure
  • left ventricular ejection fraction < 45%
  • New York Heart Association (NYHA) index ≥ 2
  • Sleep apnea syndrom confirmed by polysomnography

Exclusion Criteria:

  • Chronic Obstructive Pulmonary Disease with maximal Respiratory Volume < 50%
  • Resting oxygen saturation < 90%
  • Continuous Positive Airway Pressure (CPAP) or Adaptive Servo-Ventilation treatment
  • Life expectancy < 1 year for other medical reasons than heart failure
  • Cardiac surgery
  • Percutaneous transluminal coronary angioplasty
  • Unstable angora during the 6 last months
  • Implantation of a pacemaker or a defibrillator during the 6 last months
  • Cerebrovascular accident or Transient Ischemic Attack during the 3 last months
  • Restless legs syndrome
  • Acute myocarditis or pericarditis during the 6 last months
  • Valvular disease
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Heart failure patients with sleep apnea syndrom
For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
Other Names:
  • Embla device (Embla®, Broomfield, USA)
  • RemLogic® software, Broomfield, USA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Apnea Hypopnea Index (AHI)
Time Frame: At patient polygraphic recording
Standard nocturnal in-home ventilatory polygraphic recordings. The AHI is calculated only on nocturnal ECG analysis
At patient polygraphic recording

Secondary Outcome Measures

Outcome Measure
Time Frame
AHI in subgroup patient with sinusal rhythm
Time Frame: At patient polygraphic recording
At patient polygraphic recording
AHI in subgroup with implanted pacemaker
Time Frame: At patient polygraphic recording
At patient polygraphic recording
AHI in subgroup with atrial fibrillation
Time Frame: At patient polygraphic recording
At patient polygraphic recording
AHI in subgroup with bundle branch block
Time Frame: At patient polygraphic recording
At patient polygraphic recording

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Frederic ROCHE, MD PhD, CHU de Saint-Etienne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Actual)

November 1, 2014

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

April 10, 2014

First Submitted That Met QC Criteria

April 16, 2014

First Posted (Estimate)

April 17, 2014

Study Record Updates

Last Update Posted (Estimate)

March 31, 2015

Last Update Submitted That Met QC Criteria

March 30, 2015

Last Verified

March 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on ventilatory polygraphic recordings

Subscribe